Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 33.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 16,221 shares of the biopharmaceutical company’s stock after selling 8,054 shares during the period. Illinois Municipal Retirement Fund’s holdings in Alnylam Pharmaceuticals were worth $4,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Legal & General Group Plc bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $278,321,000. Bank of New York Mellon Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $148,128,000. Canada Pension Plan Investment Board acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $100,618,000. Korea Investment CORP bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $74,553,000. Finally, Pictet Asset Management Holding SA increased its stake in Alnylam Pharmaceuticals by 77.7% in the third quarter. Pictet Asset Management Holding SA now owns 495,168 shares of the biopharmaceutical company’s stock valued at $122,783,000 after acquiring an additional 216,555 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $8.39 during midday trading on Friday, reaching $165.04. 3,589,267 shares of the company traded hands, compared to its average volume of 3,176,010. The firm has a market cap of $22.11 billion, a PE ratio of 8.57 and a beta of 0.42. The stock’s 50-day simple moving average is $219.25 and its 200-day simple moving average is $276.00. Alnylam Pharmaceuticals, Inc. has a 12 month low of $149.18 and a 12 month high of $479.79. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the company earned $2.90 EPS. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. BMO Capital Markets reissued an “outperform” rating and issued a $290.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 30th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. UBS Group decreased their price objective on Alnylam Pharmaceuticals from $550.00 to $329.00 and set a “buy” rating on the stock in a report on Friday, October 30th. JPMorgan Chase & Co. lowered their price objective on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 30th. Finally, Chardan Capital lowered their price objective on Alnylam Pharmaceuticals from $425.00 to $375.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $305.86.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.